nodes	percent_of_prediction	percent_of_DWPC	metapath
Methysergide—HTR7—enteric nervous system—Crohn's disease	0.0904	0.264	CbGeAlD
Methysergide—HTR7—myenteric nerve plexus—Crohn's disease	0.0685	0.2	CbGeAlD
Methysergide—HTR2A—enteric nervous system—Crohn's disease	0.0564	0.164	CbGeAlD
Methysergide—HTR2A—myenteric nerve plexus—Crohn's disease	0.0427	0.125	CbGeAlD
Methysergide—Red blood cell sedimentation rate increased—Mesalazine—Crohn's disease	0.0196	0.083	CcSEcCtD
Methysergide—Telangiectasia—Prednisone—Crohn's disease	0.0118	0.0502	CcSEcCtD
Methysergide—HTR7—mouth—Crohn's disease	0.0117	0.0342	CbGeAlD
Methysergide—Gastrointestinal symptom NOS—Mesalazine—Crohn's disease	0.00896	0.038	CcSEcCtD
Methysergide—SIGMAR1—smooth muscle tissue—Crohn's disease	0.00769	0.0224	CbGeAlD
Methysergide—HTR2B—smooth muscle tissue—Crohn's disease	0.00768	0.0224	CbGeAlD
Methysergide—HTR2B—skin of body—Crohn's disease	0.00758	0.0221	CbGeAlD
Methysergide—SIGMAR1—mammalian vulva—Crohn's disease	0.00693	0.0202	CbGeAlD
Methysergide—Pleural effusion—Mesalazine—Crohn's disease	0.00688	0.0292	CcSEcCtD
Methysergide—HTR7—epithelium—Crohn's disease	0.00682	0.0199	CbGeAlD
Methysergide—Hyperaesthesia—Mesalazine—Crohn's disease	0.00671	0.0285	CcSEcCtD
Methysergide—HTR7—smooth muscle tissue—Crohn's disease	0.00657	0.0192	CbGeAlD
Methysergide—HTR2B—digestive system—Crohn's disease	0.00606	0.0177	CbGeAlD
Methysergide—HTR7—digestive system—Crohn's disease	0.00519	0.0151	CbGeAlD
Methysergide—Blood urea increased—Mesalazine—Crohn's disease	0.00497	0.0211	CcSEcCtD
Methysergide—Alopecia—Mercaptopurine—Crohn's disease	0.00431	0.0183	CcSEcCtD
Methysergide—HTR2A—epithelium—Crohn's disease	0.00425	0.0124	CbGeAlD
Methysergide—HTR2A—smooth muscle tissue—Crohn's disease	0.0041	0.012	CbGeAlD
Methysergide—Arthralgia—Mercaptopurine—Crohn's disease	0.00361	0.0153	CcSEcCtD
Methysergide—Orthostatic hypotension—Mesalazine—Crohn's disease	0.00349	0.0148	CcSEcCtD
Methysergide—SIGMAR1—lymph node—Crohn's disease	0.00347	0.0101	CbGeAlD
Methysergide—Oedema—Mercaptopurine—Crohn's disease	0.00346	0.0147	CcSEcCtD
Methysergide—HTR2B—lymph node—Crohn's disease	0.00346	0.0101	CbGeAlD
Methysergide—Thrombocytopenia—Mercaptopurine—Crohn's disease	0.00339	0.0144	CcSEcCtD
Methysergide—Eosinophilia—Mesalazine—Crohn's disease	0.00327	0.0139	CcSEcCtD
Methysergide—HTR2A—digestive system—Crohn's disease	0.00324	0.00944	CbGeAlD
Methysergide—Musculoskeletal discomfort—Mercaptopurine—Crohn's disease	0.00315	0.0134	CcSEcCtD
Methysergide—Dysuria—Mesalazine—Crohn's disease	0.00309	0.0131	CcSEcCtD
Methysergide—Neutropenia—Mesalazine—Crohn's disease	0.00309	0.0131	CcSEcCtD
Methysergide—Weight increased—Mesalazine—Crohn's disease	0.00301	0.0128	CcSEcCtD
Methysergide—Weight decreased—Mesalazine—Crohn's disease	0.00299	0.0127	CcSEcCtD
Methysergide—Gastrointestinal disorder—Mercaptopurine—Crohn's disease	0.00299	0.0127	CcSEcCtD
Methysergide—Body temperature increased—Mercaptopurine—Crohn's disease	0.00274	0.0116	CcSEcCtD
Methysergide—Oedema peripheral—Mesalazine—Crohn's disease	0.00261	0.0111	CcSEcCtD
Methysergide—Alopecia—Azathioprine—Crohn's disease	0.00257	0.0109	CcSEcCtD
Methysergide—Euphoric mood—Prednisone—Crohn's disease	0.00239	0.0102	CcSEcCtD
Methysergide—Diarrhoea—Mercaptopurine—Crohn's disease	0.00237	0.0101	CcSEcCtD
Methysergide—Ill-defined disorder—Azathioprine—Crohn's disease	0.00235	0.00995	CcSEcCtD
Methysergide—Alopecia—Mesalazine—Crohn's disease	0.00234	0.00992	CcSEcCtD
Methysergide—Thrombophlebitis—Prednisone—Crohn's disease	0.00234	0.00991	CcSEcCtD
Methysergide—Malaise—Azathioprine—Crohn's disease	0.00228	0.00967	CcSEcCtD
Methysergide—Back pain—Mesalazine—Crohn's disease	0.00223	0.00945	CcSEcCtD
Methysergide—Vomiting—Mercaptopurine—Crohn's disease	0.0022	0.00934	CcSEcCtD
Methysergide—Rash—Mercaptopurine—Crohn's disease	0.00218	0.00926	CcSEcCtD
Methysergide—Dermatitis—Mercaptopurine—Crohn's disease	0.00218	0.00925	CcSEcCtD
Methysergide—Myalgia—Azathioprine—Crohn's disease	0.00215	0.00913	CcSEcCtD
Methysergide—Arthralgia—Azathioprine—Crohn's disease	0.00215	0.00913	CcSEcCtD
Methysergide—Ill-defined disorder—Mesalazine—Crohn's disease	0.00214	0.00906	CcSEcCtD
Methysergide—Discomfort—Azathioprine—Crohn's disease	0.00213	0.00902	CcSEcCtD
Methysergide—Malaise—Mesalazine—Crohn's disease	0.00208	0.00881	CcSEcCtD
Methysergide—Nausea—Mercaptopurine—Crohn's disease	0.00206	0.00872	CcSEcCtD
Methysergide—Thrombocytopenia—Azathioprine—Crohn's disease	0.00202	0.00857	CcSEcCtD
Methysergide—Arthralgia—Mesalazine—Crohn's disease	0.00196	0.00832	CcSEcCtD
Methysergide—Chest pain—Mesalazine—Crohn's disease	0.00196	0.00832	CcSEcCtD
Methysergide—Myalgia—Mesalazine—Crohn's disease	0.00196	0.00832	CcSEcCtD
Methysergide—Discomfort—Mesalazine—Crohn's disease	0.00194	0.00822	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Azathioprine—Crohn's disease	0.00188	0.00797	CcSEcCtD
Methysergide—Oedema—Mesalazine—Crohn's disease	0.00188	0.00797	CcSEcCtD
Methysergide—Thrombocytopenia—Mesalazine—Crohn's disease	0.00184	0.00781	CcSEcCtD
Methysergide—Tachycardia—Mesalazine—Crohn's disease	0.00183	0.00778	CcSEcCtD
Methysergide—Gastrointestinal disorder—Azathioprine—Crohn's disease	0.00178	0.00756	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Mesalazine—Crohn's disease	0.00171	0.00726	CcSEcCtD
Methysergide—Feeling abnormal—Azathioprine—Crohn's disease	0.0017	0.00721	CcSEcCtD
Methysergide—Insomnia—Mesalazine—Crohn's disease	0.0017	0.00721	CcSEcCtD
Methysergide—Paraesthesia—Mesalazine—Crohn's disease	0.00169	0.00716	CcSEcCtD
Methysergide—Gastrointestinal pain—Azathioprine—Crohn's disease	0.00169	0.00716	CcSEcCtD
Methysergide—Dyspnoea—Mesalazine—Crohn's disease	0.00168	0.00711	CcSEcCtD
Methysergide—Somnolence—Mesalazine—Crohn's disease	0.00167	0.00709	CcSEcCtD
Methysergide—Dyspepsia—Mesalazine—Crohn's disease	0.00165	0.00702	CcSEcCtD
Methysergide—Neutropenia—Prednisone—Crohn's disease	0.00164	0.00694	CcSEcCtD
Methysergide—Abdominal pain—Azathioprine—Crohn's disease	0.00163	0.00692	CcSEcCtD
Methysergide—Body temperature increased—Azathioprine—Crohn's disease	0.00163	0.00692	CcSEcCtD
Methysergide—Gastrointestinal disorder—Mesalazine—Crohn's disease	0.00162	0.00688	CcSEcCtD
Methysergide—Fatigue—Mesalazine—Crohn's disease	0.00162	0.00687	CcSEcCtD
Methysergide—Constipation—Mesalazine—Crohn's disease	0.00161	0.00682	CcSEcCtD
Methysergide—Pain—Mesalazine—Crohn's disease	0.00161	0.00682	CcSEcCtD
Methysergide—Weight increased—Prednisone—Crohn's disease	0.00159	0.00675	CcSEcCtD
Methysergide—Weight decreased—Prednisone—Crohn's disease	0.00158	0.00671	CcSEcCtD
Methysergide—Feeling abnormal—Mesalazine—Crohn's disease	0.00155	0.00657	CcSEcCtD
Methysergide—Gastrointestinal pain—Mesalazine—Crohn's disease	0.00154	0.00652	CcSEcCtD
Methysergide—Body temperature increased—Mesalazine—Crohn's disease	0.00149	0.0063	CcSEcCtD
Methysergide—Abdominal pain—Mesalazine—Crohn's disease	0.00149	0.0063	CcSEcCtD
Methysergide—Diarrhoea—Azathioprine—Crohn's disease	0.00141	0.00599	CcSEcCtD
Methysergide—Dizziness—Azathioprine—Crohn's disease	0.00136	0.00579	CcSEcCtD
Methysergide—Asthenia—Mesalazine—Crohn's disease	0.00135	0.00572	CcSEcCtD
Methysergide—Vomiting—Azathioprine—Crohn's disease	0.00131	0.00556	CcSEcCtD
Methysergide—Rash—Azathioprine—Crohn's disease	0.0013	0.00552	CcSEcCtD
Methysergide—Dermatitis—Azathioprine—Crohn's disease	0.0013	0.00551	CcSEcCtD
Methysergide—Flushing—Prednisone—Crohn's disease	0.0013	0.00551	CcSEcCtD
Methysergide—Diarrhoea—Mesalazine—Crohn's disease	0.00129	0.00545	CcSEcCtD
Methysergide—Dizziness—Mesalazine—Crohn's disease	0.00124	0.00527	CcSEcCtD
Methysergide—Alopecia—Prednisone—Crohn's disease	0.00124	0.00525	CcSEcCtD
Methysergide—Nausea—Azathioprine—Crohn's disease	0.00123	0.0052	CcSEcCtD
Methysergide—Vomiting—Mesalazine—Crohn's disease	0.00119	0.00507	CcSEcCtD
Methysergide—Rash—Mesalazine—Crohn's disease	0.00119	0.00503	CcSEcCtD
Methysergide—Dermatitis—Mesalazine—Crohn's disease	0.00118	0.00502	CcSEcCtD
Methysergide—Ill-defined disorder—Prednisone—Crohn's disease	0.00113	0.0048	CcSEcCtD
Methysergide—Nausea—Mesalazine—Crohn's disease	0.00112	0.00474	CcSEcCtD
Methysergide—Malaise—Prednisone—Crohn's disease	0.0011	0.00466	CcSEcCtD
Methysergide—Convulsion—Prednisone—Crohn's disease	0.00106	0.00448	CcSEcCtD
Methysergide—Myalgia—Prednisone—Crohn's disease	0.00104	0.0044	CcSEcCtD
Methysergide—Arthralgia—Prednisone—Crohn's disease	0.00104	0.0044	CcSEcCtD
Methysergide—Discomfort—Prednisone—Crohn's disease	0.00102	0.00435	CcSEcCtD
Methysergide—Oedema—Prednisone—Crohn's disease	0.000994	0.00422	CcSEcCtD
Methysergide—Tachycardia—Prednisone—Crohn's disease	0.00097	0.00412	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Prednisone—Crohn's disease	0.000906	0.00384	CcSEcCtD
Methysergide—Insomnia—Prednisone—Crohn's disease	0.000899	0.00381	CcSEcCtD
Methysergide—Paraesthesia—Prednisone—Crohn's disease	0.000893	0.00379	CcSEcCtD
Methysergide—Dyspepsia—Prednisone—Crohn's disease	0.000875	0.00371	CcSEcCtD
Methysergide—Fatigue—Prednisone—Crohn's disease	0.000857	0.00364	CcSEcCtD
Methysergide—Constipation—Prednisone—Crohn's disease	0.00085	0.00361	CcSEcCtD
Methysergide—Feeling abnormal—Prednisone—Crohn's disease	0.000819	0.00348	CcSEcCtD
Methysergide—Gastrointestinal pain—Prednisone—Crohn's disease	0.000813	0.00345	CcSEcCtD
Methysergide—Body temperature increased—Prednisone—Crohn's disease	0.000786	0.00333	CcSEcCtD
Methysergide—Abdominal pain—Prednisone—Crohn's disease	0.000786	0.00333	CcSEcCtD
Methysergide—Asthenia—Prednisone—Crohn's disease	0.000713	0.00303	CcSEcCtD
Methysergide—Diarrhoea—Prednisone—Crohn's disease	0.00068	0.00289	CcSEcCtD
Methysergide—Dizziness—Prednisone—Crohn's disease	0.000658	0.00279	CcSEcCtD
Methysergide—Vomiting—Prednisone—Crohn's disease	0.000632	0.00268	CcSEcCtD
Methysergide—Rash—Prednisone—Crohn's disease	0.000627	0.00266	CcSEcCtD
Methysergide—Dermatitis—Prednisone—Crohn's disease	0.000626	0.00266	CcSEcCtD
Methysergide—Nausea—Prednisone—Crohn's disease	0.000591	0.00251	CcSEcCtD
Methysergide—HTR2A—SIDS Susceptibility Pathways—TNF—Crohn's disease	0.000216	0.000514	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—CCR6—Crohn's disease	0.000216	0.000513	CbGpPWpGaD
Methysergide—HTR6—GPCR ligand binding—CXCL8—Crohn's disease	0.000212	0.000503	CbGpPWpGaD
Methysergide—HTR7—GPCR ligand binding—CXCL8—Crohn's disease	0.000212	0.000503	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—RASGRP1—Crohn's disease	0.000212	0.000503	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—SEL1L—Crohn's disease	0.000211	0.0005	CbGpPWpGaD
Methysergide—HTR1D—GPCR ligand binding—CXCL8—Crohn's disease	0.000211	0.0005	CbGpPWpGaD
Methysergide—HTR2A—GPCR downstream signaling—PTGER4—Crohn's disease	0.000209	0.000497	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—GPR65—Crohn's disease	0.000207	0.000492	CbGpPWpGaD
Methysergide—HTR1A—GPCR downstream signaling—IL3—Crohn's disease	0.000206	0.00049	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—GPR65—Crohn's disease	0.000206	0.00049	CbGpPWpGaD
Methysergide—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	0.000206	0.000489	CbGpPWpGaD
Methysergide—HTR1B—GPCR ligand binding—CXCL8—Crohn's disease	0.000206	0.000489	CbGpPWpGaD
Methysergide—HTR2C—GPCR downstream signaling—IL3—Crohn's disease	0.000205	0.000488	CbGpPWpGaD
Methysergide—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	0.000205	0.000487	CbGpPWpGaD
Methysergide—HTR1F—GPCR downstream signaling—JAK2—Crohn's disease	0.000204	0.000484	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—SOCS1—Crohn's disease	0.000203	0.000483	CbGpPWpGaD
Methysergide—HTR1A—SIDS Susceptibility Pathways—IL6—Crohn's disease	0.000202	0.00048	CbGpPWpGaD
Methysergide—HTR1A—GPCR downstream signaling—RASGRP1—Crohn's disease	0.0002	0.000474	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—CCR6—Crohn's disease	0.0002	0.000474	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—CCR6—Crohn's disease	0.000199	0.000473	CbGpPWpGaD
Methysergide—HTR2C—GPCR downstream signaling—RASGRP1—Crohn's disease	0.000199	0.000472	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—CCR6—Crohn's disease	0.000198	0.00047	CbGpPWpGaD
Methysergide—HTR6—GPCR downstream signaling—IL2RA—Crohn's disease	0.000195	0.000464	CbGpPWpGaD
Methysergide—HTR7—GPCR downstream signaling—IL2RA—Crohn's disease	0.000195	0.000463	CbGpPWpGaD
Methysergide—HTR1F—Signaling by GPCR—TYK2—Crohn's disease	0.000194	0.00046	CbGpPWpGaD
Methysergide—HTR1D—GPCR downstream signaling—IL2RA—Crohn's disease	0.000194	0.00046	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—CCR6—Crohn's disease	0.000194	0.00046	CbGpPWpGaD
Methysergide—HTR2B—GPCR ligand binding—CXCL8—Crohn's disease	0.000194	0.00046	CbGpPWpGaD
Methysergide—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Crohn's disease	0.000193	0.000458	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CCR9—Crohn's disease	0.000193	0.000457	CbGpPWpGaD
Methysergide—HTR1E—GPCR downstream signaling—JAK2—Crohn's disease	0.000192	0.000456	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—SOCS1—Crohn's disease	0.000192	0.000456	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—PTGER4—Crohn's disease	0.00019	0.000451	CbGpPWpGaD
Methysergide—HTR1B—GPCR downstream signaling—IL2RA—Crohn's disease	0.00019	0.000451	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—IL3—Crohn's disease	0.000188	0.000445	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—IL3—Crohn's disease	0.000187	0.000443	CbGpPWpGaD
Methysergide—HTR1F—GPCR downstream signaling—CXCL8—Crohn's disease	0.000186	0.000442	CbGpPWpGaD
Methysergide—HTR1F—Signaling by GPCR—JAK2—Crohn's disease	0.000185	0.000439	CbGpPWpGaD
Methysergide—HTR1E—Signaling by GPCR—TYK2—Crohn's disease	0.000183	0.000434	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—CCR6—Crohn's disease	0.000182	0.000432	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—RASGRP1—Crohn's disease	0.000181	0.00043	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—RBX1—Crohn's disease	0.00018	0.000428	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—RASGRP1—Crohn's disease	0.00018	0.000428	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—RBX1—Crohn's disease	0.00018	0.000428	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—GPR65—Crohn's disease	0.000179	0.000425	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—RBX1—Crohn's disease	0.000179	0.000425	CbGpPWpGaD
Methysergide—HTR2A—GPCR downstream signaling—IL3—Crohn's disease	0.000178	0.000423	CbGpPWpGaD
Methysergide—HTR2B—GPCR downstream signaling—IL2RA—Crohn's disease	0.000178	0.000423	CbGpPWpGaD
Methysergide—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	0.000178	0.000423	CbGpPWpGaD
Methysergide—HTR6—Signaling by GPCR—IL2RA—Crohn's disease	0.000177	0.000421	CbGpPWpGaD
Methysergide—HTR7—Signaling by GPCR—IL2RA—Crohn's disease	0.000177	0.000421	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—IL2RA—Crohn's disease	0.000176	0.000418	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—PTGER4—Crohn's disease	0.000176	0.000417	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—SMAD3—Crohn's disease	0.000176	0.000417	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—PTGER4—Crohn's disease	0.000176	0.000417	CbGpPWpGaD
Methysergide—HTR1E—GPCR downstream signaling—CXCL8—Crohn's disease	0.000175	0.000416	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—RBX1—Crohn's disease	0.000175	0.000416	CbGpPWpGaD
Methysergide—HTR2A—SIDS Susceptibility Pathways—IL6—Crohn's disease	0.000175	0.000415	CbGpPWpGaD
Methysergide—HTR1E—Signaling by GPCR—JAK2—Crohn's disease	0.000175	0.000414	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—PTGER4—Crohn's disease	0.000174	0.000414	CbGpPWpGaD
Methysergide—HTR2A—GPCR downstream signaling—RASGRP1—Crohn's disease	0.000173	0.00041	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—IL2RA—Crohn's disease	0.000172	0.000409	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—PTGER4—Crohn's disease	0.000171	0.000405	CbGpPWpGaD
Methysergide—HTR1F—Signaling by GPCR—CXCL8—Crohn's disease	0.000169	0.000401	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—SMAD3—Crohn's disease	0.000166	0.000393	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—RBX1—Crohn's disease	0.000165	0.000391	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—IL2RA—Crohn's disease	0.000163	0.000386	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—IL3—Crohn's disease	0.000162	0.000384	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—IL2RA—Crohn's disease	0.000162	0.000384	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—PTGER4—Crohn's disease	0.00016	0.000381	CbGpPWpGaD
Methysergide—HTR1E—Signaling by GPCR—CXCL8—Crohn's disease	0.000159	0.000378	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—UBE2D1—Crohn's disease	0.000158	0.000376	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—UBE2D1—Crohn's disease	0.000158	0.000375	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—UBE2D1—Crohn's disease	0.000157	0.000373	CbGpPWpGaD
Methysergide—HTR1A—GPCR ligand binding—CXCL8—Crohn's disease	0.000157	0.000373	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—RASGRP1—Crohn's disease	0.000157	0.000372	CbGpPWpGaD
Methysergide—HTR2C—GPCR ligand binding—CXCL8—Crohn's disease	0.000156	0.000371	CbGpPWpGaD
Methysergide—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Crohn's disease	0.000156	0.000369	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—UBE2D1—Crohn's disease	0.000154	0.000365	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—IL2RA—Crohn's disease	0.000153	0.000364	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—RIPK2—Crohn's disease	0.000153	0.000364	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—RIPK2—Crohn's disease	0.000153	0.000364	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—RIPK2—Crohn's disease	0.000152	0.000361	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—IL3—Crohn's disease	0.00015	0.000355	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—IL3—Crohn's disease	0.000149	0.000355	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—RIPK2—Crohn's disease	0.000149	0.000354	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—IL3—Crohn's disease	0.000149	0.000352	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CCR6—Crohn's disease	0.000148	0.000351	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CCR6—Crohn's disease	0.000147	0.000349	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—IL3—Crohn's disease	0.000145	0.000345	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—RASGRP1—Crohn's disease	0.000145	0.000344	CbGpPWpGaD
Methysergide—HTR1A—GPCR downstream signaling—IL2RA—Crohn's disease	0.000145	0.000343	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—RASGRP1—Crohn's disease	0.000145	0.000343	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—UBE2D1—Crohn's disease	0.000144	0.000343	CbGpPWpGaD
Methysergide—HTR2C—GPCR downstream signaling—IL2RA—Crohn's disease	0.000144	0.000342	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—RASGRP1—Crohn's disease	0.000144	0.000341	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—RASGRP1—Crohn's disease	0.000141	0.000334	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—RIPK2—Crohn's disease	0.00014	0.000332	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—IL3—Crohn's disease	0.000137	0.000324	CbGpPWpGaD
Methysergide—HTR2A—GPCR ligand binding—CXCL8—Crohn's disease	0.000136	0.000322	CbGpPWpGaD
Methysergide—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Crohn's disease	0.000135	0.000321	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—RBX1—Crohn's disease	0.000134	0.000317	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—RBX1—Crohn's disease	0.000133	0.000315	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—RASGRP1—Crohn's disease	0.000132	0.000314	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—IL2RA—Crohn's disease	0.000131	0.000312	CbGpPWpGaD
Methysergide—HTR6—GPCR downstream signaling—JAK2—Crohn's disease	0.000131	0.000312	CbGpPWpGaD
Methysergide—HTR7—GPCR downstream signaling—JAK2—Crohn's disease	0.000131	0.000311	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—SOCS1—Crohn's disease	0.000131	0.000311	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—SOCS1—Crohn's disease	0.000131	0.000311	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—IL2RA—Crohn's disease	0.000131	0.00031	CbGpPWpGaD
Methysergide—HTR1D—GPCR downstream signaling—JAK2—Crohn's disease	0.00013	0.000309	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—SOCS1—Crohn's disease	0.00013	0.000309	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—PTGER4—Crohn's disease	0.00013	0.000309	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—PTGER4—Crohn's disease	0.000129	0.000307	CbGpPWpGaD
Methysergide—HTR1B—GPCR downstream signaling—JAK2—Crohn's disease	0.000128	0.000303	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CCR6—Crohn's disease	0.000128	0.000303	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—SOCS1—Crohn's disease	0.000127	0.000302	CbGpPWpGaD
Methysergide—HTR6—Signaling by GPCR—TYK2—Crohn's disease	0.000125	0.000297	CbGpPWpGaD
Methysergide—HTR2A—GPCR downstream signaling—IL2RA—Crohn's disease	0.000125	0.000297	CbGpPWpGaD
Methysergide—HTR7—Signaling by GPCR—TYK2—Crohn's disease	0.000125	0.000296	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—TYK2—Crohn's disease	0.000124	0.000294	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—TYK2—Crohn's disease	0.000121	0.000288	CbGpPWpGaD
Methysergide—HTR2B—GPCR downstream signaling—JAK2—Crohn's disease	0.00012	0.000285	CbGpPWpGaD
Methysergide—HTR6—GPCR downstream signaling—CXCL8—Crohn's disease	0.00012	0.000285	CbGpPWpGaD
Methysergide—HTR7—GPCR downstream signaling—CXCL8—Crohn's disease	0.00012	0.000284	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—SOCS1—Crohn's disease	0.00012	0.000284	CbGpPWpGaD
Methysergide—HTR6—Signaling by GPCR—JAK2—Crohn's disease	0.000119	0.000283	CbGpPWpGaD
Methysergide—HTR7—Signaling by GPCR—JAK2—Crohn's disease	0.000119	0.000283	CbGpPWpGaD
Methysergide—HTR1D—GPCR downstream signaling—CXCL8—Crohn's disease	0.000119	0.000282	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—JAK2—Crohn's disease	0.000118	0.000281	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—UBE2D1—Crohn's disease	0.000117	0.000278	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—UBE2D1—Crohn's disease	0.000117	0.000277	CbGpPWpGaD
Methysergide—HTR1B—GPCR downstream signaling—CXCL8—Crohn's disease	0.000116	0.000276	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—JAK2—Crohn's disease	0.000116	0.000275	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—RBX1—Crohn's disease	0.000115	0.000274	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—TYK2—Crohn's disease	0.000115	0.000272	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—TYK2—Crohn's disease	0.000114	0.000271	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—RIPK2—Crohn's disease	0.000114	0.00027	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—IL2RA—Crohn's disease	0.000113	0.000269	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—SMAD3—Crohn's disease	0.000113	0.000269	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—SMAD3—Crohn's disease	0.000113	0.000268	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—RIPK2—Crohn's disease	0.000113	0.000268	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PTGER4—Crohn's disease	0.000112	0.000267	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—SMAD3—Crohn's disease	0.000112	0.000267	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—IL3—Crohn's disease	0.000111	0.000263	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—IL3—Crohn's disease	0.00011	0.000262	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—SMAD3—Crohn's disease	0.00011	0.000261	CbGpPWpGaD
Methysergide—HTR2B—GPCR downstream signaling—CXCL8—Crohn's disease	0.000109	0.00026	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—JAK2—Crohn's disease	0.000109	0.00026	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—JAK2—Crohn's disease	0.000109	0.000258	CbGpPWpGaD
Methysergide—HTR6—Signaling by GPCR—CXCL8—Crohn's disease	0.000109	0.000258	CbGpPWpGaD
Methysergide—HTR7—Signaling by GPCR—CXCL8—Crohn's disease	0.000109	0.000258	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—TYK2—Crohn's disease	0.000108	0.000257	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—CXCL8—Crohn's disease	0.000108	0.000256	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—RASGRP1—Crohn's disease	0.000107	0.000254	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—RASGRP1—Crohn's disease	0.000107	0.000253	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—CXCL8—Crohn's disease	0.000106	0.000251	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—IL2RA—Crohn's disease	0.000105	0.000249	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—IL2RA—Crohn's disease	0.000105	0.000249	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—IL2RA—Crohn's disease	0.000104	0.000247	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—SMAD3—Crohn's disease	0.000103	0.000245	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—JAK2—Crohn's disease	0.000103	0.000245	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—IL2RA—Crohn's disease	0.000102	0.000242	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—UBE2D1—Crohn's disease	0.000101	0.00024	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—CXCL8—Crohn's disease	9.98e-05	0.000237	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—CXCL8—Crohn's disease	9.94e-05	0.000236	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—RIPK2—Crohn's disease	9.81e-05	0.000233	CbGpPWpGaD
Methysergide—HTR1A—GPCR downstream signaling—JAK2—Crohn's disease	9.72e-05	0.000231	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—SOCS1—Crohn's disease	9.71e-05	0.00023	CbGpPWpGaD
Methysergide—HTR2C—GPCR downstream signaling—JAK2—Crohn's disease	9.67e-05	0.00023	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—SOCS1—Crohn's disease	9.66e-05	0.000229	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—IL3—Crohn's disease	9.57e-05	0.000227	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—IL2RA—Crohn's disease	9.57e-05	0.000227	CbGpPWpGaD
Methysergide—HTR1F—Signaling by GPCR—IL6—Crohn's disease	9.49e-05	0.000225	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—CXCL8—Crohn's disease	9.41e-05	0.000223	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—RASGRP1—Crohn's disease	9.26e-05	0.00022	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—TYK2—Crohn's disease	9.26e-05	0.00022	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—TYK2—Crohn's disease	9.21e-05	0.000219	CbGpPWpGaD
Methysergide—HTR1E—Signaling by GPCR—IL6—Crohn's disease	8.95e-05	0.000212	CbGpPWpGaD
Methysergide—HTR1A—GPCR downstream signaling—CXCL8—Crohn's disease	8.87e-05	0.000211	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—JAK2—Crohn's disease	8.83e-05	0.00021	CbGpPWpGaD
Methysergide—HTR2C—GPCR downstream signaling—CXCL8—Crohn's disease	8.83e-05	0.00021	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—JAK2—Crohn's disease	8.78e-05	0.000208	CbGpPWpGaD
Methysergide—HTR2A—GPCR downstream signaling—JAK2—Crohn's disease	8.4e-05	0.000199	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—SOCS1—Crohn's disease	8.39e-05	0.000199	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—SMAD3—Crohn's disease	8.38e-05	0.000199	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—SMAD3—Crohn's disease	8.34e-05	0.000198	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—CXCL8—Crohn's disease	8.06e-05	0.000191	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—STAT3—Crohn's disease	8.03e-05	0.00019	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—CXCL8—Crohn's disease	8.02e-05	0.00019	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—TYK2—Crohn's disease	8e-05	0.00019	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—IL2RA—Crohn's disease	7.76e-05	0.000184	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—IL2RA—Crohn's disease	7.72e-05	0.000183	CbGpPWpGaD
Methysergide—HTR2A—GPCR downstream signaling—CXCL8—Crohn's disease	7.67e-05	0.000182	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—JAK2—Crohn's disease	7.63e-05	0.000181	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—STAT3—Crohn's disease	7.57e-05	0.00018	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—TYK2—Crohn's disease	7.39e-05	0.000175	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—TYK2—Crohn's disease	7.38e-05	0.000175	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—TYK2—Crohn's disease	7.33e-05	0.000174	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—SMAD3—Crohn's disease	7.24e-05	0.000172	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—TYK2—Crohn's disease	7.18e-05	0.00017	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—JAK2—Crohn's disease	7.05e-05	0.000167	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—JAK2—Crohn's disease	7.04e-05	0.000167	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—JAK2—Crohn's disease	6.99e-05	0.000166	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—CXCL8—Crohn's disease	6.96e-05	0.000165	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—JAK2—Crohn's disease	6.85e-05	0.000162	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—TYK2—Crohn's disease	6.74e-05	0.00016	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—IL2RA—Crohn's disease	6.7e-05	0.000159	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—JAK2—Crohn's disease	6.43e-05	0.000153	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—CXCL8—Crohn's disease	6.43e-05	0.000153	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—CXCL8—Crohn's disease	6.42e-05	0.000152	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—CXCL8—Crohn's disease	6.38e-05	0.000151	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—CXCL8—Crohn's disease	6.25e-05	0.000148	CbGpPWpGaD
Methysergide—HTR6—Signaling by GPCR—IL6—Crohn's disease	6.12e-05	0.000145	CbGpPWpGaD
Methysergide—HTR7—Signaling by GPCR—IL6—Crohn's disease	6.11e-05	0.000145	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—IL6—Crohn's disease	6.07e-05	0.000144	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—IL6—Crohn's disease	5.94e-05	0.000141	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—CXCL8—Crohn's disease	5.87e-05	0.000139	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—IL6—Crohn's disease	5.61e-05	0.000133	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—IL6—Crohn's disease	5.58e-05	0.000132	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—TYK2—Crohn's disease	5.47e-05	0.00013	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—TYK2—Crohn's disease	5.44e-05	0.000129	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—IL6—Crohn's disease	5.29e-05	0.000126	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—JAK2—Crohn's disease	5.22e-05	0.000124	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—JAK2—Crohn's disease	5.19e-05	0.000123	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—STAT3—Crohn's disease	5.17e-05	0.000123	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—STAT3—Crohn's disease	5.17e-05	0.000123	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—STAT3—Crohn's disease	5.13e-05	0.000122	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—STAT3—Crohn's disease	5.03e-05	0.000119	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CXCL8—Crohn's disease	4.76e-05	0.000113	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CXCL8—Crohn's disease	4.74e-05	0.000112	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—TYK2—Crohn's disease	4.72e-05	0.000112	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—STAT3—Crohn's disease	4.72e-05	0.000112	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—IL6—Crohn's disease	4.53e-05	0.000107	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—JAK2—Crohn's disease	4.51e-05	0.000107	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—IL6—Crohn's disease	4.5e-05	0.000107	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CXCL8—Crohn's disease	4.11e-05	9.76e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—IL6—Crohn's disease	3.91e-05	9.28e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—STAT3—Crohn's disease	3.83e-05	9.09e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—STAT3—Crohn's disease	3.81e-05	9.04e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—IL6—Crohn's disease	3.61e-05	8.57e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—IL6—Crohn's disease	3.61e-05	8.56e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—IL6—Crohn's disease	3.58e-05	8.51e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—IL6—Crohn's disease	3.51e-05	8.33e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—STAT3—Crohn's disease	3.31e-05	7.85e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—IL6—Crohn's disease	3.3e-05	7.83e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—IL6—Crohn's disease	2.67e-05	6.35e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—IL6—Crohn's disease	2.66e-05	6.31e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—IL6—Crohn's disease	2.31e-05	5.48e-05	CbGpPWpGaD
